No abstract

No abstract

two-phase amorphous alloys. The initial microstructure of these rapidly quenched alloys is composed of Ti-based, amorphous, spherical, nanometer-sized particles embedded in a Y-based amorphous matrix, with particle size dependent on the alloy composition. The Ti-based powders were extracted from the two-phase amorphous alloys through selective dissolution of the Y-rich matrix in a 0.1 M HNO 3 solution. The powders of size ranging between 20 and 200 nm have smooth and spherical morphology, and exhibit different magnetic behavior than the bulk alloy of identical composition.

Oncology Group performance status score of 0e1 (odds ratio [OR], 3.07; P ¼ 0.003) and no initial central nervous system (CNS) metastases (OR, 2.43; P ¼ 0.014) were independent predictors of PD in the initially involved sites alone. The 1e3 metastases at the start of EGFR-TKI treatment was not a predictor of PD in the initially involved sites alone (OR, 2.05; P ¼ 0.297). Multivariate logistic regression analyses of the clinical factors at 12 weeks from the start of EGFR-TKI treatment revealed that 1e3 residual metastases (OR, 3.07; P ¼ 0.003) and no residual CNS metastases (OR, 3.26; P ¼ 0.014) were independent predictors of PD in the initially involved sites alone. Additional multivariate logistic regression analyses of the clinical factors at 12 weeks from the start of EGFR-TKI treatment revealed that 1e3 residual metastases (OR, 3.18; P ¼ 0.002) and no residual CNS metastases (OR 2.77; P ¼ 0.026) were independent predictors of PD in residually involved sites alone. Conclusion: The results of this study showed that the initial 1e3 metastases at the start of EGFR-TKI treatment was not a predictor of PD in the initially involved sites alone, and that 1e3 residual metastases at 12 weeks from the start of EGFR-TKI treatment and no residual CNS metastases were independent predictors of PD in the residually involved sites alone in patients with EGFR-mutated NSCLC. Accordingly, the oligometastatic state at 12 weeks from the start of EGFR-TKI treatment might be a candidate for LAT to all sites of disease.